Side effects of methylphenidate in children with attention deficit hyperactivity disorder: a systemic, placebo-controlled evaluation - PubMed (original) (raw)
Affiliations
- PMID: 2196520
Clinical Trial
Side effects of methylphenidate in children with attention deficit hyperactivity disorder: a systemic, placebo-controlled evaluation
R A Barkley et al. Pediatrics. 1990 Aug.
Abstract
The frequency and severity of 17 side effects presumably associated with stimulant medication were assessed during a rigorous, triple-blind, placebo-controlled, crossover evaluation of methylphenidate, 0.3 and 0.5 mg/kg twice a day, in 83 children with attention deficit hyperactivity disorder. Side effects were rated by parents and teachers at the end of each weekly drug condition. Three children (3.6%) had side effects that were sufficiently serious to warrant immediate discontinuation of medication. Parent ratings indicated that only the side effects of decreased appetite, insomnia, stomachaches, and headaches increased significantly in frequency and severity during the two active medication doses as compared with the placebo condition. Fewer than half of the children experienced these side effects and among those who did, ratings of mean severity remained in the mild range. Teacher ratings showed little change over drug conditions, except on ratings of staring, sadness, and anxiety, which declined with increasing dose of medication. Parent ratings indicated that only the side effects of decreased appetite, insomnia, stomachaches, and headaches increased significantly in frequency and severity during the two active medication doses as compared with the placebo condition. Fewer than half of the children experienced these side effects and among those who did, ratings of mean severity remained in the mild range. Teacher ratings showed little change over drug conditions, except on ratings of staring, sadness, and anxiety, which declined with increasing dose of medication. Surprisingly, a high frequency of these behavior side effects were reported during the placebo condition. Stimulant medication within this therapeutic range, therefore, results in few, generally mild side effects.(ABSTRACT TRUNCATED AT 250 WORDS)
Similar articles
- Methylphenidate dosing: twice daily versus three times daily.
Stein MA, Blondis TA, Schnitzler ER, O'Brien T, Fishkin J, Blackwell B, Szumowski E, Roizen NJ. Stein MA, et al. Pediatrics. 1996 Oct;98(4 Pt 1):748-56. Pediatrics. 1996. PMID: 8885956 Clinical Trial. - Placebo-controlled evaluation of Ritalin side effects.
Ahmann PA, Waltonen SJ, Olson KA, Theye FW, Van Erem AJ, LaPlant RJ. Ahmann PA, et al. Pediatrics. 1993 Jun;91(6):1101-6. Pediatrics. 1993. PMID: 8502509 Clinical Trial. - Randomized, controlled, crossover trial of methylphenidate in pervasive developmental disorders with hyperactivity.
Research Units on Pediatric Psychopharmacology Autism Network. Research Units on Pediatric Psychopharmacology Autism Network. Arch Gen Psychiatry. 2005 Nov;62(11):1266-74. doi: 10.1001/archpsyc.62.11.1266. Arch Gen Psychiatry. 2005. PMID: 16275814 Clinical Trial. - A dose-response study of OROS methylphenidate in children with attention-deficit/hyperactivity disorder.
Stein MA, Sarampote CS, Waldman ID, Robb AS, Conlon C, Pearl PL, Black DO, Seymour KE, Newcorn JH. Stein MA, et al. Pediatrics. 2003 Nov;112(5):e404. doi: 10.1542/peds.112.5.e404. Pediatrics. 2003. PMID: 14595084 Clinical Trial. - Treatment of attention deficit hyperactivity disorder in children and adolescents: safety considerations.
Wolraich ML, McGuinn L, Doffing M. Wolraich ML, et al. Drug Saf. 2007;30(1):17-26. doi: 10.2165/00002018-200730010-00003. Drug Saf. 2007. PMID: 17194168 Review.
Cited by
- Ameliorating attention problems in children with sickle cell disease: a pilot study of methylphenidate.
Daly B, Kral MC, Brown RT, Elkin D, Madan-Swain A, Mitchell M, Crosby L, Dematteo D, Larosa A, Jackson S. Daly B, et al. J Dev Behav Pediatr. 2012 Apr;33(3):244-51. doi: 10.1097/DBP.0b013e31824ba1b5. J Dev Behav Pediatr. 2012. PMID: 22343483 Free PMC article. Clinical Trial. - Methylphenidate and its isomers: their role in the treatment of attention-deficit hyperactivity disorder using a transdermal delivery system.
Heal DJ, Pierce DM. Heal DJ, et al. CNS Drugs. 2006;20(9):713-38. doi: 10.2165/00023210-200620090-00002. CNS Drugs. 2006. PMID: 16953648 Review. - Outcomes of a 12-week ecologically valid observational study of first treatment with methylphenidate in a representative clinical sample of drug naïve children with ADHD.
Kaalund-Brok K, Houmann TB, Hebsgaard MB, Lauritsen MG, Lundstrøm LH, Grønning H, Darling L, Reinert-Petersen S, Petersen MA, Jepsen JRM, Pagsberg AK, Plessen KJ, Rasmussen HB, Jeppesen P; INDICES. Kaalund-Brok K, et al. PLoS One. 2021 Oct 21;16(10):e0253727. doi: 10.1371/journal.pone.0253727. eCollection 2021. PLoS One. 2021. PMID: 34673771 Free PMC article. Clinical Trial. - Gastrointestinal adverse events during methylphenidate treatment of children and adolescents with attention deficit hyperactivity disorder: A systematic review with meta-analysis and Trial Sequential Analysis of randomised clinical trials.
Holmskov M, Storebø OJ, Moreira-Maia CR, Ramstad E, Magnusson FL, Krogh HB, Groth C, Gillies D, Zwi M, Skoog M, Gluud C, Simonsen E. Holmskov M, et al. PLoS One. 2017 Jun 15;12(6):e0178187. doi: 10.1371/journal.pone.0178187. eCollection 2017. PLoS One. 2017. PMID: 28617801 Free PMC article. Review. - Titrating Optimal Dose of Osmotic-Controlled Release Oral Delivery (OROS)-Methylphenidate and Its Efficacy and Safety in Korean Children with ADHD: A Multisite Open Labeled Study.
Song DH, Choi S, Joung YS, Ha EH, Kim BN, Shin YJ, Shin D, Yoo HJ, Cheon KA. Song DH, et al. Psychiatry Investig. 2012 Sep;9(3):257-62. doi: 10.4306/pi.2012.9.3.257. Epub 2012 Sep 6. Psychiatry Investig. 2012. PMID: 22993525 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Medical